|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15 Pt 2
|
|
pubmed:dateCreated |
2007-8-2
|
|
pubmed:abstractText |
Only 10% of patients with relapsed non-small cell lung cancer (NSCLC) treated with chemotherapy or erlotinib have a partial response to treatment, and nearly all eventually recur and die from their NSCLC. Agents that can block other pathways in addition to the epidermal growth factor receptor signals may improve the therapeutic efficacy of erlotinib. Everolimus (RAD001) is an inhibitor of the mammalian target of rapamycin, which is downstream of initial epidermal growth factor receptor signaling. A trial combining erlotinib with everolimus has been undertaken for patients with relapsed NSCLC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
s4628-31
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17671154-Animals,
pubmed-meshheading:17671154-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17671154-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:17671154-Clinical Trials, Phase I as Topic,
pubmed-meshheading:17671154-Humans,
pubmed-meshheading:17671154-Lung Neoplasms,
pubmed-meshheading:17671154-Neoplasm Recurrence, Local,
pubmed-meshheading:17671154-Protein Kinases,
pubmed-meshheading:17671154-Quinazolines,
pubmed-meshheading:17671154-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17671154-Sirolimus,
pubmed-meshheading:17671154-TOR Serine-Threonine Kinases
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
|
|
pubmed:affiliation |
Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Boston, Massachusetts 02115, USA. bejohnson@partners.org
|
|
pubmed:publicationType |
Journal Article,
Review
|
